

Speaker:
IGCS16 CME Disclo

<u>Last Name</u>	<u>First Name</u>	<u>Roles</u>	<u>Relationships</u>	<u>Company Name</u>	<u>Honoraria/ Expenses</u>
Abu-Rustum	Nadeem R.	Scientific/Education Planning Committee Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No		
Amant	Frederic	Scientific/Education Planning Committee	No		
Angioli	Roberto	Invited Speaker/Faculty	No		
Barakat	Richard	Board of Directors	No		
Bats	Anne-Sophie	Invited Speaker/Faculty	Yes	Roche and Intuitive Surgical	X
Benedetti Panici	Pierluigi	Poster/Oral Presenter	No		
Berek	Jonathan	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	Yes	Tesaro	
Bernardini	Marcus	Invited Speaker/Faculty	Yes	AstraZeneca	
Bhatla	Neerja	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No		
Bookman	Michael	Invited Speaker/Faculty	Yes	McKesson Specialty Health	

--	--	--	--

Genentech	
AstraZeneca	
Clovis	
Endocyte	

				Immunogen	
				Tesaro	
Botha	Hennie	Invited Speaker/Faculty	Yes	GlaxoSmithKline	X
				Merck	X
Boyd	Jeff	Invited Speaker/Faculty	No		
Buda	Alessandro	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No		
Chi	Dennis	Invited Speaker/Faculty	No		
Coleman	Robert L	Invited Speaker/Faculty Session Moderator/Chair/Coordinator Poster/Oral Presenter Board of Directors	Yes	Abbott Laboratories	
				Advaxis	
				AstraZeneca	
				Bayer	

				Genentech	
				Janssen Pharmaceuticals	
Colombo	Nicoletta	Invited Speaker/Faculty	Yes	Roche	
				Pharma Mar	
				Amgen	
				Merck	
				Glaxo	
				MSD	
				Clovis	
				AstraZeneca	
Correa	Raimundo	Invited Speaker/Faculty Poster/Oral Presenter	No		
Covens	Allan	Session Moderator/Chair/Coordinator	No		
Creutzberg	Carien	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No		
Denny	Lynette	Scientific/Education Planning Committee Session Moderator/Chair/Coordinator	Yes	Merck	X
				GlaxoSmithKline	X
Denschlag	Dominik	Invited Speaker/Faculty	Yes	Hoffmann-La Roche	X
				KLS Martin	
				Serag-Wiesner	X
Domingo	Efren	Invited Speaker/Faculty	No		
Dowdy	Sean	Scientific/Education Planning Committee Invited Speaker/Faculty Session Moderator/Chair/Coordinator Poster/Oral Presenter Committee (CME Research other)	No		

Farthing	Alan	Invited Speaker/Faculty	No		
Fotopoulou	Christina	Invited Speaker/Faculty	No		
Friedlander	Michael	Session Moderator/Chair/Coordinator	No		
Ganesan	Prasanth	Invited Speaker/Faculty	No		
Gerda Zahl Eriksson	Ane	Scientific/Education Planning Committee	No		
Gershenson	David	Invited Speaker/Faculty	Yes	Johnson&Johnson	
				Biogen Idec	
				celgene	
				Pfizer	

				Proctor&Gamble	
Gotlieb	Walter	Scientific/Education Planning Committee Session Moderator/Chair/Coordinator	Yes	AstraZeneca	X
				Roche	X
Gwin	Katja	Invited Speaker/Faculty	No		
Hacker	Neville	Invited Speaker/Faculty	No		
Halaska	Michael	Invited Speaker/Faculty	No		
Harter	Philipp	Invited Speaker/Faculty	Yes	AstraZeneca	
		Session Moderator/Chair/Coordinator		Genentech	
Kim	Jae-Weon	Scientific/Education Planning Committee Invited Speaker/Faculty	No		
		Session Moderator/Chair/Coordinator			
Kimura	Tadashi	Invited Speaker/Faculty	Yes	Merck	X
				GE Healthcare	X
				Johnson&Johnson	X
				Siemens Healthcare	X
				Hisamitsu Pharmaceutical Co.Ltd.	X
				Chyugai Parmaceutical Co.Ltd.	X
				Taihou Pharmaceutical Co.Ltd.	X
				Mochida Pharmaceutical Co.Ltd.	X
				Fuji Parmaceutical Co.Ltd.	X
				Yakuruto Co.Ltd.	X
Kumarasamy	Suresh	Invited Speaker/Faculty	Yes	Bayer	X
				AstraZeneca	X
				Merck	X
Leitao	Mario	Scientific/Education Planning Committee Invited Speaker/Faculty	Yes	Intuitive	X
				Novadaq	X

Mahner	Sven	Scientific/Education Planning Committee Invited Speaker/Faculty	No		
Mariani	Andrea	Invited Speaker/Faculty	No		
Marth	Christian	Scientific/Education Planning Committee Invited Speaker/Faculty Session Moderator/Chair/Coordinator Poster/Oral Presenter	No		
Massuger	Leon	Invited Speaker/Faculty	No		
Mbatani	Nomonde	Invited Speaker/Faculty	No		
McAlpine	Jessica N.	Invited Speaker/Faculty	Yes	Merck	X
Mccluggage	Glenn	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No		
McNally	Orla	Invited Speaker/Faculty	No		
Menon	Santosh	Invited Speaker/Faculty	No		
Menon	Usha	Invited Speaker/Faculty	Yes	Abcodia	
Mileshkin	Linda	Invited Speaker/Faculty	Yes	Merck	X
Mirza	Mansoor Raza	Scientific/Education Planning Committee Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No		
Monk	Bradley	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	Yes	Advaxis	
				Amgen	

Insys	
Clovis	
Janssen Pharmaceuticals	X
Merck	
Myriad	X

Pfizer	
Tesaro	
Roche	X
Morphotek	
Mateon(formally OxiGENE)	

				Gradalis	
Nam	Joo-Hyun	Scientific/Education Planning Committee Session Moderator/Chair/Coordinator	No		
Naumann	Robert Wendel	Invited Speaker/Faculty	No		
Ngan	Yuen Sheung Hextan	Invited Speaker/Faculty	No		
O'Cearbhaill	Roisin	Invited Speaker/Faculty	No		
Obermair	Andreas	Scientific/Education Planning Committee	Yes	Covidien	
		Invited Speaker/Faculty		Ethicon-endo	
		Session Moderator/Chair/Coordinator		SurgicalPerformance	
Odunsi	Kunle	Invited Speaker/Faculty	No		
Okamoto	Aikou	Session Moderator/Chair/Coordinator	No		
Ordi	Jaume	Invited Speaker/Faculty	No		
Petru	Edgar	Invited Speaker/Faculty	No		
		Session Moderator/Chair/Coordinator			
Pignata	Sandro	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	Yes	AstraZeneca	X
Plante	Marie	Scientific/Education Planning Committee Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No		
Polterauer	Stephan	Invited Speaker/Faculty	No		
Pötter	Richard	Invited Speaker/Faculty	No		

Prat	Jaime	Scientific/Education Planning Committee Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No		
Pujade-Lauraine	Eric	Invited Speaker/Faculty	Yes	Hoffmann-La Roche	X
				AstraZeneca	X
				Pfizer	
Quinn	Michael	Scientific/Education Planning Committee Invited Speaker/Faculty Session Moderator/Chair/Coordinator Board of Directors	Yes	Roche and Tesaro	
Raspagliesi	Francesco	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No		
Reimer	Daniel	Invited Speaker/Faculty	Yes	AstraZeneca	X
Reinhaller	Alexander	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No		
Rob	Lukas	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	Yes	GlaxoSmithKline	
Sabbatini	Paul	Invited Speaker/Faculty	Yes	Bristol-Myers Squibb	
Schmeler	Kathleen	Session Moderator/Chair/Coordinator	No		
Seckl	Michael	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	Yes	Bristol-Myers Squibb	
Sehouli	Jalid	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No		

Silva	Elvio	Scientific/Education Planning Committee Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No		
Simmonds	Hannah	Invited Speaker/Faculty	No		
Singh	Naveena	Invited Speaker/Faculty	No		
Small	Bill (William), Jr	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	Yes	Zeiss	X
Soslow	Robert	Invited Speaker/Faculty	Yes	EMD Serono, Cambridge Univ Press, Springer Publishing, NIH, DOD	X
Tanaka	Yusuke	Invited Speaker/Faculty	No		
Taylor	Alexandra	Invited Speaker/Faculty Session Moderator/Chair/Coordinator Poster/Oral Presenter	No		
Temkin	Sarah	Invited Speaker/Faculty	No		
Teunissen	Saskia	Invited Speaker/Faculty	No		
Toral	Jean Anne	Session Moderator/Chair/Coordinator	No		
Touhami	Omar	Invited Speaker/Faculty	No		
van der Zee	Ate	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No		
Vandecaveye	Vincent	Invited Speaker/Faculty	No		
Vergote	Ignace	Invited Speaker/Faculty	No		
Woelber	Linn	Invited Speaker/Faculty Poster/Oral Presenter	Yes	Medac Oncology	X
				Hoffmann-La Roche	X
				Jenapharm	X
Wright	Jason	Invited Speaker/Faculty	No		

s' Portal

Disclosure Form Results

<u>Consulting/ Advisory Board</u>	<u>Funded Research</u>	<u>Royalties/ Patent</u>	<u>Stock Options</u>	<u>Ownership/ Equity Position</u>	<u>Employee</u>	<u>Other</u>	<u>Off Label Product Use</u>
	X						
X							
					X		multiple investigational and approved agents including standard chemotherapy, bevacizumab, PARP inhibitors, targeted agents, and immune checkpoint inhibitors

X						Protocol Steering Committee	multiple investigational and approved agents including standard chemotherapy, bevacizumab, PARP inhibitors, targeted agents, and immune checkpoint inhibitors
X							multiple investigational and approved agents including standard chemotherapy, bevacizumab, PARP inhibitors, targeted agents, and immune checkpoint inhibitors
X							multiple investigational and approved agents including standard chemotherapy, bevacizumab, PARP inhibitors, targeted agents, and immune checkpoint inhibitors
X							multiple investigational and approved agents including standard chemotherapy, bevacizumab, PARP inhibitors, targeted agents, and immune checkpoint inhibitors

						Data Monitoring Committee	multiple investigational and approved agents including standard chemotherapy, bevacizumab, PARP inhibitors, targeted agents, and immune checkpoint inhibitors
X							multiple investigational and approved agents including standard chemotherapy, bevacizumab, PARP inhibitors, targeted agents, and immune checkpoint inhibitors
	X						Parp inhibitors and Combinations for research purposes
X	X						Parp inhibitors and Combinations for research purposes
X	X						Parp inhibitors and Combinations for research purposes
X							Parp inhibitors and Combinations for research purposes

X	X						Parp inhibitors and Combinations for research purposes
	X						Parp inhibitors and Combinations for research purposes
	X					Clovis	Parp inhibitors and Combinations for research purposes
X							
X							
X							
X							
X							
X							
X							
X	X						

				X			Off-label use of chemotherapy, hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers
				X			Off-label use of chemotherapy, hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers
				X			Off-label use of chemotherapy, hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers
				X			Off-label use of chemotherapy, hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers

		X					Off-label use of chemotherapy, hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers
		X					Off-label use of chemotherapy, hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers
	X						Off-label use of chemotherapy, hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers
X							Off-label use of chemotherapy, hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers
					X		Off-label use of chemotherapy, hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers

				X			Off-label use of chemotherapy, hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers
X	X						
X							
X							
	X						
X							
X							
X							

	X		X				
X							I will be discussing the NCCN guidelines and clinical trials relevant to cervical and ovarian cancer which may involve off-label and/or investigations products.
X	X						I will be discussing the NCCN guidelines and clinical trials relevant to cervical and ovarian cancer which may involve off-label and/or investigations products.

	X						I will be discussing the NCCN guidelines and clinical trials relevant to cervical and ovarian cancer which may involve off-label and/or investigations products.
X							I will be discussing the NCCN guidelines and clinical trials relevant to cervical and ovarian cancer which may involve off-label and/or investigations products.
X							I will be discussing the NCCN guidelines and clinical trials relevant to cervical and ovarian cancer which may involve off-label and/or investigations products.
	X						I will be discussing the NCCN guidelines and clinical trials relevant to cervical and ovarian cancer which may involve off-label and/or investigations products.
X	X						I will be discussing the NCCN guidelines and clinical trials relevant to cervical and ovarian cancer which may involve off-label and/or investigations products.

X							I will be discussing the NCCN guidelines and clinical trials relevant to cervical and ovarian cancer which may involve off-label and/or investigations products.
X							I will be discussing the NCCN guidelines and clinical trials relevant to cervical and ovarian cancer which may involve off-label and/or investigations products.
	X						I will be discussing the NCCN guidelines and clinical trials relevant to cervical and ovarian cancer which may involve off-label and/or investigations products.
X							I will be discussing the NCCN guidelines and clinical trials relevant to cervical and ovarian cancer which may involve off-label and/or investigations products.
							I will be discussing the NCCN guidelines and clinical trials relevant to cervical and ovarian cancer which may involve off-label and/or investigations products.

X							I will be discussing the NCCN guidelines and clinical trials relevant to cervical and ovarian cancer which may involve off-label and/or investigations products.
X	X						I will be discussing the NCCN guidelines and clinical trials relevant to cervical and ovarian cancer which may involve off-label and/or investigations products.
X							I will be discussing the NCCN guidelines and clinical trials relevant to cervical and ovarian cancer which may involve off-label and/or investigations products.
	X						I will be discussing the NCCN guidelines and clinical trials relevant to cervical and ovarian cancer which may involve off-label and/or investigations products.
X							I will be discussing the NCCN guidelines and clinical trials relevant to cervical and ovarian cancer which may involve off-label and/or investigations products.

X							avelumab, pembrolizumab, atezoluzumab
X							avelumab, pembrolizumab, atezoluzumab
X							avelumab, pembrolizumab, atezoluzumab
							avelumab, pembrolizumab, atezoluzumab
X							
X							
	X						
X							I may mention the use of pembrolizumab to salvage patients who have failed everything else

